Kestrel Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, in Patients with KRAS-drive…

Kestrel has entered into a warrant agreement with AbbVie with an exclusive option for AbbVie to acquire the Company based on ...
Fierce Biotech

AbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition

After debunking earlier rumors that it was acquiring RAS superstar Revolution Medicines, AbbVie is now taking a more ...
Yahoo Finance

Kestrel Therapeutics Announces IND Clearance by U.S. FDA of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, Enabling Initiation of Phase 1 Trial

WATERTOWN, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Kestrel Therapeutics Inc. (“Kestrel” or the “Company”), a clinical stage biotechnology company developing next-generation small-molecule inhibitors ...
BioWorld

Kestrel’s KST-6051 gains IND clearance for KRAS-driven cancers

Kestrel Therapeutics Inc. has obtained IND approval from the FDA for KST-6051, an oral, small-molecule pan-KRAS inhibitor being developed for the treatment of KRAS-driven cancers. A first-in-human ...
BioWorld

CSPC’s SYS-6051 cleared for clinic in China for solid tumors

CSPC Pharmaceutical Group Ltd.’s SYS-6051 has gained clinical trial clearance from China’s National Medical Products ...
manilatimes

Kestrel Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, in Patients with KRAS-driven ...

Kestrel has entered into a warrant agreement with AbbVie with an exclusive option for AbbVie to acquire the Company based on defined development milestones WATERTOWN, Mass., April 28, 2026 (GLOBE ...